Lausanne, Switzerland, May 11, 2005 Debiopharm S.A., the independent drug-development company specialising in oncology, endocrinology and niche products, is pleased to acknowledge a new marketing and supply agreement between Paladin Labs Inc. (Paladin) (TSX: PLB), a leading Canadian specialty pharmaceutical company and Watson Pharma, Inc., a subsidiary of Watson Pharmaceuticals, Inc. (Watson) to market Trelstar® 3.75 mg and Trelstar® LA 11.25 mg (triptorelin pamoate for injectable suspension) in Canada. Debiopharm developed both products and was responsible for submitting the registration file to the US Food and Drug Administration (FDA) and to Health Canada, the Canadian health authorities. Trelstar® 3.75 mg and Trelstar® LA 11.25 mg are respectively one and three-month sustained release, injectable formulations of luteinizing hormone-releasing hormone (LHRH) agonists and have been approved by Health Canada for the palliative treatment of advanced prostate cancer. Trelstar® 3.75 mg is also approved for the treatment of endometriosis.
